Click here - to use the wp menu builder

BryoLogyx Names Omar Duramad, Ph.D., as Chief Scientific Officer

DANVILLE, Calif.–(BUSINESS WIRE)–BryoLogyx appoints Omar Duramad, Ph.D. as Chief Scientific Officer to lead preclinical development of bryostatin and analogues…

http://www.businesswire.com/news/home/20190730005289/en/BryoLogyx-Names-Omar-Duramad-Ph.D.-Chief-Scientific

BryoLogyx Names Omar Duramad, Ph.D., as Chief Scientific Officer

Recent Articles

VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan

Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer

Ault Global Holdings Announces Adtech Pharma, Inc., an Innovative Biotech, Appoints Jodi Brichan to Its Board of Directors

Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults

Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib